Tecarfarin
As of the edition of 20 October 2026, Tecarfarin is a small molecule: went quiet in 2020; acts on VKORC1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2020
- Kind
- Small molecule
- Registered trials
- 5, 0 stopped early
- Disease areas
- Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route A because of this drug.
Companies on route A for this drug
In the product3 companies are on route A because of Tecarfarin.
See the 3 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| VKORC1 | Vitamin K epoxide reductase complex subunit 1 | Q9BQB6 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 2 | 0 | 0 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| ARYx Therapeutics | Lead sponsor of trials | 2006 to now |
| Espero Biopharma | Lead sponsor of trials | 2018 to now |
| Lee's Pharmaceutical | Lead sponsor of trials | 2018 to now |